275 related articles for article (PubMed ID: 11590151)
1. Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein.
Bussell R; Eliezer D
J Biol Chem; 2001 Dec; 276(49):45996-6003. PubMed ID: 11590151
[TBL] [Abstract][Full Text] [Related]
2. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
Bussell R; Eliezer D
Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050
[TBL] [Abstract][Full Text] [Related]
3. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
4. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
5. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
[TBL] [Abstract][Full Text] [Related]
6. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
Rochet JC; Conway KA; Lansbury PT
Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
[TBL] [Abstract][Full Text] [Related]
9. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
Li J; Uversky VN; Fink AL
Neurotoxicology; 2002 Oct; 23(4-5):553-67. PubMed ID: 12428728
[TBL] [Abstract][Full Text] [Related]
10. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
[TBL] [Abstract][Full Text] [Related]
11. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
12. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
[TBL] [Abstract][Full Text] [Related]
13. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
14. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons.
Saha AR; Hill J; Utton MA; Asuni AA; Ackerley S; Grierson AJ; Miller CC; Davies AM; Buchman VL; Anderton BH; Hanger DP
J Cell Sci; 2004 Mar; 117(Pt 7):1017-24. PubMed ID: 14996933
[TBL] [Abstract][Full Text] [Related]
16. Site-specific perturbations of alpha-synuclein fibril structure by the Parkinson's disease associated mutations A53T and E46K.
Lemkau LR; Comellas G; Lee SW; Rikardsen LK; Woods WS; George JM; Rienstra CM
PLoS One; 2013; 8(3):e49750. PubMed ID: 23505409
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
[TBL] [Abstract][Full Text] [Related]
18. Distinct residual and disordered structures of alpha-synuclein analyzed by amide-proton exchange and NMR signal intensity.
Okuwaki R; Shinmura I; Morita S; Matsugami A; Hayashi F; Goto Y; Nishimura C
Biochim Biophys Acta Proteins Proteom; 2020 Sep; 1868(9):140464. PubMed ID: 32497661
[TBL] [Abstract][Full Text] [Related]
19. Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation.
Bertoncini CW; Fernandez CO; Griesinger C; Jovin TM; Zweckstetter M
J Biol Chem; 2005 Sep; 280(35):30649-52. PubMed ID: 16020550
[TBL] [Abstract][Full Text] [Related]
20. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.
Coskuner O; Wise-Scira O
ACS Chem Neurosci; 2013 Jul; 4(7):1101-13. PubMed ID: 23607785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
